2. Search Result
Search Result
Results for "

SMARCA2/4

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12409
    PFI-3
    3 Publications Verification

    		 Epigenetic Reader Domain Cancer
    PFI-3 is a selective, potent and cell-permeable SMARCA2/4 bromodomain inhibitor with a Kd of 89 nM.
    PFI-3
  • HY-156568A
    SMD-3040 TFA

    		Ligands for Target Protein for PROTAC Cancer
    SMD-3040 TFA is a selective degrader of SMARCA2. SMD-3040 TFA contains SMARCA2/4 ligands, linker and VHL ligands and can be used for PROTAC drug synthesis. SMD-3040 TFA exhibits strong tumor growth inhibition in tumor xenograft models .
    SMD-3040 TFA
  • HY-400685
    SMD-3040 intermediate-2

    		Others Cancer
    SMD-3040 intermediate-2 is an intermediate in the synthesis of SMD-3040 (HY-156568). SMD-3040 contains SMARCA2/4 ligands, linker and VHL ligands and is a selective SMARCA2 degrader. MD-3040 can be used for ADC drug synthesis and has strong tumor growth inhibition in tumor xenograft models .
    SMD-3040 intermediate-2
  • HY-153425
    PROTAC SMARCA2 degrader-2

    		PROTACs Cancer
    PROTAC SMARCA2 degrader-2 is a potent and selective SMARCA2/4 PROTAC degrader with an IC50 of <0.1 μΜ in HeLa HiBiT assay. PROTAC SMARCA2 degrader-2 is extracted from patent WO2023287787A1 and has the potential for SMARCA4-related or deficient cancer research .
    PROTAC <em>SMARCA2</em> degrader-2
  • HY-156568
    SMD-3040

    		Epigenetic Reader Domain PROTACs Cancer
    SMD-3040 is a potent and selective of SMARCA2 PROTAC degrader (DC50: 12 nM). SMD-3040 contains SMARCA2/4 ligand, linker and VHL ligand. SMD-3040 demonstrates excellent degradation selectivity for SMARCA2 protein over SMARCA4 protein.SMD-3040 achieves strong tumor growth inhibition in xenograft models .
    SMD-3040
  • HY-144896
    FHT-1015
    1 Publications Verification

    		 Epigenetic Reader Domain Cancer
    FHT-1205 is a potent SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor with IC50s of ≤10 nM (WO2020160180A1; compound 67) .
    FHT-1015
  • HY-144897
    FHT-1204

    		Epigenetic Reader Domain Cancer
    FHT-1204 is a potent SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor with IC50s of ≤10 nM (WO2020160180A1; compound 70) .
    FHT-1204
  • HY-149458
    FHT-2344

    		Epigenetic Reader Domain Cancer
    FHT-2344 is a SMARCA4/SMARCA2 ATPase inhibitor with IC50 values of 0.026 μM and 0.013 μM, respectively. FHT-2344 has anticancer activity .
    FHT-2344
  • HY-145446
    SGC-SMARCA-BRDVIII

    		Epigenetic Reader Domain Metabolic Disease
    SGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2/4 and PB1(5), with Kds of 35 nM, 36 nM, and 13 nM, respectively. SGC-SMARCA-BRDVIII also inhibits PB1(2) and PB1(3), with Kds of 3.7 and 2.0 μM, respectively. SGC-SMARCA-BRDVIII can block adipogenesis of 3T3-L1 murine fibroblasts [2].
    SGC-<em>SMARCA</em>-BRDVIII
  • HY-144835
    FHD-286
    1 Publications Verification

    		 Oxidative Phosphorylation Epigenetic Reader Domain Cancer
    FHD-286 is a selective, oral inhibitor of SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor. FHD-286 has the potential for the research of BAF (BRG1/BRM-associated factor)-related disorders such as acute myeloid leukemia .
    FHD-286

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: